April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.
The trial was testing the combination of Oncomed's tarextumab and chemotherapy, compared with chemotherapy and a placebo. The main goal was to slow the progression of the disease.
Last week, the company said it would discontinue a trial testing its experimental drug, demcizumab, as an initial treatment for advanced pancreatic cancer. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)
PRESS DIGEST - Wall Street Journal - June 23
June 23 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
Big Oil turns to big data to save big money on drilling
June 23 In today's U.S. shale fields, tiny sensors attached to production gear harvest data on everything from pumping pressure to the heat and rotational speed of drill bits boring into the rocky earth.